Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric fidaxomicin versus vancomycin for Clostridioides difficile-associated diarrhea
2013-000508-40Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2014
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Clostridioides difficile colitis (CDI) comparing Fidaxomicin with Vancomycin (2 arms). Primary endpoint: Confirmed clinical response. Started Aug 2014; status: completed.
02
Drugs
fidaxomicinvancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2013-000508-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000508-40.